KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Net Income: 2018-2024

Historic Net Income for Royalty Pharma (RPRX) over the last 7 years, with Dec 2024 value amounting to $1.3 billion.

  • Royalty Pharma's Net Income fell 44.91% to $444.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 24.00%. This contributed to the annual value of $1.3 billion for FY2024, which is 21.72% down from last year.
  • Per Royalty Pharma's latest filing, its Net Income stood at $1.3 billion for FY2024, which was down 21.72% from $1.7 billion recorded in FY2023.
  • Royalty Pharma's 5-year Net Income high stood at $1.7 billion for FY2020, and its period low was $230.1 million during FY2022.
  • Its 3-year average for Net Income is $1.1 billion, with a median of $1.3 billion in 2024.
  • Its Net Income has fluctuated over the past 5 years, first plummeted by 81.46% in 2022, then skyrocketed by 638.96% in 2023.
  • Over the past 5 years, Royalty Pharma's Net Income (Yearly) stood at $1.7 billion in 2020, then declined by 27.07% to $1.2 billion in 2021, then crashed by 81.46% to $230.1 million in 2022, then skyrocketed by 638.96% to $1.7 billion in 2023, then dropped by 21.72% to $1.3 billion in 2024.